SignalXSignalX

IRMD IRADIMED CORP

Q3 2025 10-Q
Filed: Nov 3, 2025Period ending Sep 30, 2025
Health Care
Surgical & Medical Instruments & ApparatusSEC EDGAR
IRADIMED CORP Overview

IRADIMED CORP (IRMD) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 3, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

  • • Revenue $21.2M for Q3 2025, up 16% YoY from $18.3M in Q3 2024; nine months revenue $61.1M, up 13% from $53.9M
  • • Gross margin 78% Q3 2025 vs 77% Q3 2024; nine months margin steady at 77% both years
+3 more insights

Risk Factors

  • • No newly added risk factors disclosed this quarter; section continues prior risks without material updates
  • • Most materially updated risk: increased regulatory expenses driven by expanded FDA requirements and ongoing post-market surveillance programs
+3 more insights

Get deeper insights on IRADIMED CORP

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.